Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Malignant Melanoma

  Free Subscription

Articles published in Curr Opin Oncol

Retrieve available abstracts of 16 articles:
HTML format

Single Articles

    March 2024
  1. PADONOU F, Vanhulst T, Langouo-Fontsa MD
    Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
    Curr Opin Oncol. 2024;36:63-68.
    PubMed     Abstract available

    January 2024
  2. BENHIMA N, Belbaraka R, Fontsa ML
    Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
    Curr Opin Oncol. 2024 Jan 3. doi: 10.1097/CCO.0000000000001014.
    PubMed     Abstract available

    September 2023
  3. KINDT N, Kotecki N, Awada A
    Preclinical models to understand the biology and to discover new targets in brain metastases.
    Curr Opin Oncol. 2023;35:436-440.
    PubMed     Abstract available

    July 2023
  4. SAUDE-CONDE R, Nguyen D, Hendlisz A
    Immunotherapies in non-metastatic gastrointestinal cancers.
    Curr Opin Oncol. 2023;35:334-346.
    PubMed     Abstract available

    March 2023
  5. D'ALISE AM, Scarselli E
    Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.
    Curr Opin Oncol. 2023;35:94-99.
    PubMed     Abstract available

  6. SCHWARZE JK, Geeraerts X, Tuyaerts S, Neyns B, et al
    Current "state of the art" on dendritic cell-based cancer vaccines in melanoma.
    Curr Opin Oncol. 2023;35:87-93.
    PubMed     Abstract available

    January 2023
  7. ELLINGSEN EB, Bjorheim J, Gaudernack G
    Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
    Curr Opin Oncol. 2023 Jan 17. doi: 10.1097/CCO.0000000000000922.
    PubMed     Abstract available

    September 2022
  8. BAEUERLE PA, Wesche H
    T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Curr Opin Oncol. 2022;34:552-558.
    PubMed     Abstract available

    March 2022
    Harnessing dendritic cells for innovative therapeutic cancer vaccines.
    Curr Opin Oncol. 2022;34:161-168.
    PubMed     Abstract available

    January 2022
  10. DEVAUX A, Baurain JF
    Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors.
    Curr Opin Oncol. 2022 Jan 25. pii: 00001622-900000000-98953.
    PubMed     Abstract available

  11. AWADA G, Neyns B
    Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
    Curr Opin Oncol. 2022 Jan 19. pii: 00001622-900000000-98954.
    PubMed     Abstract available

  12. KRAYEM M, Ghanem GE, Van Gestel D
    Recent advances in radiosensitivity determinants in melanoma.
    Curr Opin Oncol. 2022 Jan 10. pii: 00001622-900000000-98957.
    PubMed     Abstract available

    March 2021
  13. MOREIRA A, Lebbe C, Heinzerling L
    MAPK blockade, toxicities, pathogenesis and management.
    Curr Opin Oncol. 2021;33:139-145.
    PubMed     Abstract available

    January 2021
  14. TROJANIELLO C, Vitale MG, Ascierto PA
    Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
    Curr Opin Oncol. 2021;Publish Ahead of Print.
    PubMed     Abstract available

    December 2020
  15. DUMAZ N, Lebbe C
    New perspectives on targeting RAF, MEK and ERK in melanoma.
    Curr Opin Oncol. 2020;Publish Ahead of Print.
    PubMed     Abstract available

  16. TETU P, Vercellino L, Reger de Moura C, Baroudjian B, et al
    Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data.
    Curr Opin Oncol. 2020 Dec 9. doi: 10.1097/CCO.0000000000000706.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.